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Angiographic Findings of the Multicenter Randomized
Study With the Sirolimus-Eluting Bx Velocity
Balloon-Expandable Stent (RAVEL)
Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size
E. Regar, MD; P.W. Serruys, MD, PhD; C. Bode, MD; C. Holubarsch, MD; J.L. Guermonprez, MD;
W. Wijns, MD; A. Bartorelli, MD; C. Constantini, MD; M. Degertekin, MD; K. Tanabe, MD;
C. Disco, MSc; E. Wuelfert, BPharm, MSc, M.C. Morice, MD; on Behalf of the RAVEL Study Group
Background—Restenosis remains the major limitation of coronary catheter-based intervention. In small vessels, the
amount of neointimal tissue is disproportionately greater than the vessel caliber, resulting in higher restenosis rates. In
the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, 40% of the
vessels were small (2.5 mm). The present study evaluates the relationship between angiographic outcome and vessel
diameter for sirolimus-eluting stents.
Methods and Results—Patients were randomized to receive either an 18-mm bare metal Bx VELOCITY (BS group,
n118), or a sirolimus-eluting Bx VELOCITY stent (SES group, n120). Subgroups were stratified into terciles
according to their reference diameter (RD; stratum I, RD 2.36 mm; stratum II, RD 2.36 mm to 2.84 mm; stratum III,
RD 2.84 mm). At 6-month follow-up, the restenosis rate in the SES group was 0% in all strata (versus 35%, 26%, and
20%, respectively, in the BS group). In-stent late loss was 0.010.25 versus 0.800.43 mm in stratum I, 0.010.38
versus 0.880.57 mm in stratum II, and 0.060.35 versus 0.740.57 mm in stratum III (SES versus BS). In SES,
the minimal lumen diameter (MLD) remained unchanged ( 0.72 to 0.72 mm) in 97% of the lesions and increased
(late gain, MLD 0.72 mm) in 3% of the lesions. Multivariate predictors for late loss were treatment allocation
(P0.001) and postprocedural MLD (P0.008).
Conclusions—Sirolimus-eluting stents prevent neointimal proliferation and late lumen loss irrespective of the vessel
diameter. The classic inverse relationship between vessel diameter and restenosis rate was seen in the bare stent group
but not in the sirolimus-eluting stent group. (Circulation. 2002;106:1949-1956.)
Key Words: stents  drugs  angioplasty  restenosis
Restenosis remains the major limitation of coronarycatheter-based intervention.1 In stented vessels, the ma-
jor contributor to restenosis is neointimal proliferation, which
is a ubiquitous, local, vascular reaction to catheter-induced
vessel injury.2 Vessel diameter is an established predictor of
angiographic outcome after catheter-based intervention, with
a higher restenosis rate in smaller vessels.3 This is because of
the disproportionately greater amount of neointimal tissue
relative to the vessel caliber.4 Although coronary stents
provide major benefits versus simple balloon angioplasty by
inhibiting acute vessel closure, early vessel recoil, and late
vessel constriction, they stimulate neointimal proliferation.
Therefore, restenosis rates in small vessels may be similarly
high with these 2 treatment modalities.5,6 Inhibition of neo-
intimal proliferation by local pharmacological interventions
is a promising concept. Sirolimus (rapamycin) is an immu-
nosuppressive drug approved for the prevention of renal
transplant rejection. It also has potent antiproliferative and
antimigratory effects on vascular smooth muscle cells.7 Re-
cent clinical experience with sirolimus-eluting coronary
stents has shown excellent results, with 0% restenosis at
4-month,8 6-month,9 and 12-month follow-up.10 At the time
of these pilot studies, sirolimus-eluting stents were only
available in a 3.0-mm or 3.5-mm diameter, limiting treatment
to relatively large vessels. In the Randomized Study With the
Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent
(RAVEL) trial, a smaller sirolimus-eluting stent with a
diameter of 2.5 mm was available, and it allowed smaller
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vessels to be stented. This small sirolimus-eluting stent was
used in 18% of patients.11 The present study investigated the
relationship between angiographic outcome and vessel diam-
eter for sirolimus-eluting stents compared with bare metal
stents.
Methods
Patients and Stent Implantation
The patient population and stent implantation technique have been
described in detail elsewhere.11 The 238 patients enrolled in the
RAVEL trial had a single de novo lesion of a native coronary artery.
Patients were randomized (double-blind) for implantation of either
an 18-mm uncoated bare metal Bx VELOCITY stent (BS), or a
sirolimus-eluting Bx VELOCITY balloon-expandable stent (Cordis
Corp, Johnson & Johnson) (SES). All drug-eluting Bx VELOCITY
stents contained 140 g sirolimus/cm2 (10%). Total sirolimus
content was 153 g (10%) on the 6-cell stent (2.5 and 3.0 mm in
diameter) and 180 g (10%) on the 7-cell stent (3.5 mm in
diameter). This difference in content was due to the differences in the
surface area of the two stents. Stent implantation was performed in
the conventional manner after predilation. Postdilatation was per-
formed as necessary to achieve a residual stenosis below 20% with
TIMI grade III flow. Patients received aspirin (at least 100 mg)
indefinitely with either clopidogrel (75 mg daily) or ticlopidine (250
mg, twice daily) for 8 weeks.
Quantitative Coronary Angiographic Analysis
Coronary angiograms were obtained in multiple views after intracor-
onary injection of nitrates. Quantitative analyses by edge-detection
techniques were performed by an independent core laboratory
(Cardialysis BV) blinded to treatment allocation. Reference diameter
(RD), minimal luminal diameter (MLD), and degree of stenosis (as
percentage of diameter) were measured before dilatation, at the end
of the procedure, and at a 6-month follow-up. Restenosis was defined
as 50% diameter stenosis at follow-up. Late loss was defined as
MLD after the procedure minus MLD at follow-up.
The target lesion was defined as the stent segment plus 5 mm
proximal and 5 mm distal to the edge of the stent. The vessel
segment was defined as the segment bounded by side branches
proximal and distal to the stent segment (Figure 1).
The accuracy of the method has been reported in detail.12 Given
the accuracy of quantitative coronary angiography for MLD mea-
surements, we used 2 standard deviations12 as the cut-off point for
the classification of late loss indicating whether MLD was un-
changed (no loss, MLD 0.72 to 0.72 mm), reduced (late loss,
MLD 0.72 mm), or larger (late gain, MLD 0.72 mm,
“negative late loss”) at follow-up.13
Subgroup Definition
Both groups were stratified according to their vessel diameter.
Vessel diameter was defined as the baseline RD in the vessel
segment analysis before intervention. The terciles for the RD were
calculated and used as cut-off points for subgroup definition.
Sample Size Estimation and Statistical Analysis
Based on Late Loss
A sample size of 95 in each group had 87% power to detect a
difference in means of 0.25 mm (the difference between a bare stent
late loss mean, B, of 0.80 mm and a sirolimus stent late loss mean,
S, of 0.55 mm), assuming that the common standard deviation is
0.55 using a 2-group t test with a 0.05 1-sided significance level. The
sample size was increased to 110 in each group to account for
noncompliance to 6-month angiographic follow-up.
Data are presented as meanSD or proportions. For comparison
of continuous data, a 2-tailed Student’s t test was performed. A value
of P0.05 was considered significant. To identify the factors that
might be related to late lumen loss, linear regression analyses were
performed. Predictors were chosen by stepwise linear regression
using an entry criterion of 0.20 and a stay criterion of 0.05.
Results
The 238 patients were randomly assigned (SES, n120; BS,
n118). There were no significant differences with regard to
procedural success (96.6% versus 93.1%), stents per patient
(1.00.3 versus 1.10.3), and nominal stent diameter
(3.060.34 mm versus 3.1029 mm; SES versus BS,
respectively).
Before the procedure, RD (2.600.54 mm versus
2.640.52 mm) and MLD (0.940.31 mm versus
0.950.35 mm) were similar in both groups. After the proce-
dure, there were also no meaningful differences (postprocedural
RD, 2.620.44 mm versus 2.680.45 mm; postprocedural
MLD, 2.430.41 mm versus 2.410.40 mm; SES versus BS,
respectively). At follow-up, the SES group showed a larger
MLD (2.420.49 mm versus 1.640.59 mm, P0.001) and
lower late lumen loss (0.010.33 mm versus 0.800.53 mm,
P0.001). Binary restenosis was 0.0% in the SES group and
26.6% in the BS group (P0.001).
Figure 2 illustrates the relation between postprocedural
MLD and MLD at follow-up. In the SES group, the MLD
(Figure 2A) remained basically unchanged; late loss was seen
in 1 lesion and late gain was seen in 4 lesions (3%). In
contrast, lumen reduction over time was seen in approxi-
mately half of the BS patients (n55, 47%), and no late gain
Figure 1. I, Vessel segment (VS) was defined as
the segment bounded by side branches proximal
(A) and distal (A) to the stent segment. II, Target
lesion (TL) encompassed the stent segment and
edge segments. The length of the vessel covered
by stent struts defined the stent segment (from B
to B). The edge segments encompassed the ves-
sel 5 mm proximal (C) and distal (C) to the stent.
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was seen. A similar pattern was found for the mean diameter
over the entire length of the stent (Figure 2B).
Stratification
Subgroups were stratified according to their RD (Figure 3).
There were no significant differences in baseline patient and
lesion characteristics in the SES and BS subgroups. There
were also no significant differences in procedural parameters
(Table 1).
Analysis of the strata revealed a higher proportion of
diabetic patients in small and intermediate vessels. The stent
implantation procedure showed a decreasing balloon to artery
ratio (stratum I versus stratum III: P0.001 in both, BS and
SES group) and increasing inflation pressure from stratum I
to stratum III (stratum I versus stratum III: P0.01 SES
group; P0.22 BS group).
Table 2 summarizes the key angiographic data. Vessel
segment analysis showed similar preprocedural and postpro-
cedural MLD in both treatment groups throughout corre-
sponding strata.
Restenosis, Late Lumen Loss, and Vessel Size
At follow-up, the MLD was consistently larger in the SES
groups. In all strata, the restenosis rate was 0% in the SES
groups, with extremely low and consistently uniform late
loss. In the BS strata, the classic inverse relationship between
restenosis rate and vessel diameter was seen. Restenosis rate
virtually doubled with decreasing vessel size from 20% in
large vessels (stratum III) to 35% in small vessels (stratum I).
The amount of late loss, however, was similar in the 3 groups
(0.80 mm in stratum I, 0.88 mm in stratum II, and 0.74 mm
in stratum III). Therefore, the observed increase in restenosis
rate in smaller vessels in this series is driven largely by the
relative amount of obstruction as a function of vessel diam-
eter rather than being due to an absolute increase in neointi-
mal hyperplasia in smaller vessels.
Subsegment Analysis
Vessel Segment Analysis
Vessel segment analysis revealed minimal late gain in both
the MLD and RD over time in SES subgroups but not in BS
groups (Table 2).
Target Lesion Analysis (Including Stent Segment and the
Proximal and Distal Edges)
The SES subgroups showed minimal late loss at the stent segment
(0.010.25 mm, 0.010.38 mm, and0.060.35 mm in strata I,
II, and III, respectively) and proximal edges (0.040.34 mm,
0.080.42 mm, and 0.030.43 mm in strata I, II, and III, respec-
tively), whereas the distal SES edges had minimal late gain
(0.050.29 mm, 0.140.31 mm, and 0.090.31 mm in
strata I, II, and III, respectively). In contrast, the BS subgroups
showed pronounced late loss in the stent segment and moderate late
loss at the proximal and distal edges.
Multivariate Analysis
Univariate predictors for late loss included treatment alloca-
tion and postprocedural MLD (Table 3). Multivariate predic-
tors for late loss were treatment allocation (P0.001) and the
MLD after the procedure (P0.008) (Table 4).
Figure 3. Subgroup stratification: cumulative frequency distribu-
tion curve of the preinterventional reference diameter. Arrows
indicate cut-off values at the 33rd and the 66th percentile.
Figure 2. Relationship between measurements after implanta-
tion and at 6-month follow-up for the SES group and the BS
group: MLD (A), mean diameter over the entire length of the
stent (B). Dashed lines indicate the range of 0.72 mm change
in diameter.
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TABLE 1. Baseline Characteristics for Sirolimus-Eluting and Bare Stents,
Stratified by Vessel Size
Stratum/Parameter SES BS Difference (95% CI) P
I
n 42 37      
Age, y 6212 6210 0.4 (5.0, 4.3)   
Male sex 73.8 75.7 1.9 (21.0, 17.3)   
Diabetes mellitus 19.0 27.0 8.0 (26.6, 10.6)   
Unstable angina 40.4 48.6 8.1 (30.0, 13.7)   
Lesion length, mm 9.53.2 8.82.8 0.70 (0.64, 2.04)   
Discrete (10 mm) 64.3 64.9 0.6 (21.7, 20.6)   
Tubular (10–20 mm) 35.7 35.1 0.6 (20.6, 21.7)   
Lesion type (AHA/ACC)
A 9.5 2.7 6.8 (3.5, 17.1)   
B1 28.6 32.4 3.9 (24.2, 16.5)   
B2 61.9 64.9 3.0 (24.2, 18.3)   
C 0 0 0   
Mean stent diameter, mm 2.80.2 2.90.2 0.10 (0.22, 0.01) 0.08
3.5 2.3 5.4 3.0 (11.6, 5.4) 0.59
3.0 58.1 73.0 14.8 (35.3, 5.7) 0.24
2.5 39.5 21.6 17.9 (1.8, 37.6) 0.10
Balloon-artery ratio 1.30.1 1.30.2 0 (0.09, 0.09) 0.96
Maximal inflation pressure, atm 14.23.5 14.23.4 0.03 (1.5, 1.5) 0.97
Postprocedural dissection 1.00
None 76.2 75.7 0.5 (18.4, 19.4)   
Type A 7.1 2.7 4.4 (4.9, 13.8)   
Type B 9.5 18.9 9.4 (24.8, 6.0)   
Type C 7.1 2.7 4.4 (4.9, 13.8)   
Other 0 0 0   
II
n 40 38      
Age, y 6110 5911 1.3 (3.5, 6.2)   
Male sex 72.5 81.6 9.1 (27.6, 9.5)   
Diabetes mellitus 22.5 21.1 1.4 (16.9, 19.8)   
Unstable angina 51.2 54.0 2.7 (25.2, 19.6)   
Lesion length, mm 9.02.9 8.42.2 0.54 (0.62, 1.70)   
Discrete (10 mm) 89.5 83.8 5.7 (9.7, 21.1)   
Tubular (10–20 mm) 10.5 18.9 8.7 (24.5, 7.1)
Lesion type (AHA/ACC)
A 5.1 5.4 0.3 (10.3, 9.8)   
B1 53.8 35.1 18.7 (3.2, 40.7)   
B2 41.0 59.5 18.4 (40.5, 3.7)   
C 0 0 0   
Mean stent diameter, mm 3.00.3 3.10.2 0.03 (0.16, 0.09) 0.60
3.5 26.1 26.3 0.1 (19.4, 19.1) 1.00
3.0 61.9 68.4 6.5 (27.3, 14.3) 0.64
2.5 11.9 5.2 6.6 (5.4, 18.7) 0.44
Balloon-artery ratio 1.10.1 1.20.2 0.1 (0.1,0.03) 0.008
Maximal inflation pressure, atm 14.73.1 15.52.6 0.7 (2.0, 0.5) 0.26
Postprocedural dissection 0.62
None 71.8 64.9 6.9 (14.0, 27.8)   
Type A 10.3 21.6 11.4 (27.7, 5.0)   
Type B 7.7 8.1 0.4 (12.6, 11.7)   
Type C 5.1 2.7 2.4 (6.2, 11.1)   
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Discussion
We investigated the relationship between vessel diameter and
angiographic outcome 6 months after sirolimus-eluting stent
implantation in patients in the RAVEL trial. The main findings
of the study are that sirolimus-eluting stents prevent restenosis
irrespective of vessel diameter and do not show the classic
inverse relationship of vessel diameter to restenosis rate.
Quantitative coronary angiography convincingly demon-
strates the absence of neointimal proliferation and restenosis
in all patients treated with the sirolimus-eluting stent within
the first 6 months, unlike those treated with bare metal stents.
This truly remarkable finding creates a totally new paradigm
in interventional cardiology and puts paid to the well-
established existing paradigm, the classic inverse relationship
between vessel diameter and restenosis rate.3
Prevention of Neointima Growth
Neointimal growth is a normal reaction to vascular injury.
Smooth muscle cells are considered to be the main compo-
nents of coronary artery neointima after stent implantation,
and the severity of the reaction may be modulated by the
extent of stent-induced vessel injury14 and the inflammatory
reaction around the stent struts.15
Vessel injury is influenced by stent surface material,
geometric configuration, implantation technique, and vessel
size.16 Neointimal hyperplasia and persistent tissue prolifer-
ation are related to the degree of vessel injury (balloon/artery
ratio	inflation pressure).17
In our patients, 2 stent configurations (6-cell and 7-cell
designs) were used. Stent implantation technique varied with
vessel size. In small vessels, a relatively higher balloon to
artery ratio of 1.3 was achieved, whereas the balloon to artery
ratio was lower (1.0) in large vessels. Conversely, the
inflation pressure was lower in small vessels than in larger
vessels (14 atm versus 16 atm).
In the present study, the effectiveness of the sirolimus-
eluting stent was extremely strong and was affected neither
by established risk factors for restenosis nor by stent config-
uration, balloon to artery ratio, or balloon pressure. Other
than treatment allocation, the only independent predictor for
late loss was the postprocedural MLD.
The very low late loss, which is consistently reported in all
studies with sirolimus-eluting stents,8–10 raised concerns
about late lumen enlargement. In the present study, there was
evidence of late lumen gain (negative late lumen loss) in 3%
of SES patients.
TABLE 1. (Continued)
Stratum/Parameter SES BS Difference (95% CI) P
Other 5.1 0 5.1 (1.8, 12.1)   
III
n 38 42      
Age, y 629 579 5.3 (1.2, 9.4)   
Male sex 63.2 88.1 24.9 (43.1,6.7)   
Diabetes mellitus 5.3 16.7 11.4 (24.7, 1.9)   
Unstable angina 54.0 52.3 1.6 (20.3, 23.7)   
Lesion length, mm 10.13.8 11.43.4 1.27 (2.91, 0.38)   
Discrete (10 mm) 85.7 74.4 11.4 (6.6, 29.3)  
Tubular (10–20 mm) 14.3 25.6 11.4 (29.3, 6.6)   
Lesion type (AHA/ACC)
A 7.9 4.8 3.1 (7.6, 13.9)   
B1 34.2 35.7 1.5 (22.4, 19.4)   
B2 57.9 59.5 1.6 (23.2, 20.0)   
C 0 0 0   
Mean stent diameter, mm 3.30.2 3.20.2 0.07 (0.04, 0.18) 0.22
3.5 64.9 51.2 13.7 (7.7, 35.1) 0.26
3.0 35.1 48.8 13.7 (35.1, 7.7) 0.26
2.5 0 0 0   
Balloon-artery ratio 1.00.1 1.00.1 0.03 (0.05, 0.10) 0.51
Maximal inflation pressure, atm 16.23.6 15.13.2 1.0 (0.4, 2.5) 0.18
Postprocedural dissection 0.76
None 86.8 83.3 3.5 (12.1, 19.1)   
Type A 0 7.1 7.1 (14.9, 0.6)   
Type B 7.9 9.5 1.6 (14.0,, 10.7)   
Type C 5.3 0 5.3 (1.8, 12.4)   
Other 0 0 0   
AHA/ACC indicates American Heart Association/American College of Cardiology classification.
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Furthermore, minimal but consistently negative late loss
was seen at the distal edges of the stent. This phenomenon
might be related to the downstream elution of the drug.
Although the finding of late lumen gain in a very small
percentage of patients is interesting, it is worth noting that
there have been no clinical events attributable to this phe-
nomenon in the patients treated with the sirolimus-eluting
stent at 1-year follow-up, or in the patients of Sousa et al10 for
up to 2 years. Mechanistic angiographic analysis of the Sao
Paulo series10 showed stable lumen dimensions with minimal
late lumen loss between 4- and 12-month follow-up (in-stent
MLD 2.9005 mm at 4 months and 2.870.4 mm at 12
month; slow-release group) that matches well with the stable
clinical result.
The Importance of Late Loss as a Predictor
of Restenosis
The classic inverse relationship between vessel diameter and
restenosis rate was not seen in the sirolimus-eluting stent
group. This offers new therapeutic options for small vessels,
in which conventional stenting is of questionable value.5 This
is especially true for diabetic patients, who often have small
arteries because of diffuse coronary artery disease.18 In
addition, they frequently have an exaggerated neointimal
TABLE 2. Quantitative Coronary Angiography Analysis of Sirolimus-Eluting Stents and Bare Stents, Stratified by
Vessel Size
Stratum/Parameter
Vessel Segment Stent Segment
Target Lesion
Proximal Edge Distal Edge
SES BS SES BS SES BS SES BS
I
RD, mm
Before 2.090.21 2.070.21                  
After 2.300.30 2.260.33 2.380.26 2.400.31            
Follow-up 2.340.42 2.110.33 2.450.38 2.120.32            
MLD, mm
Before 0.820.19 0..770.18 0.820.19 0.770.18 1.840.38 1.710.40 1.530.31 1.560.36
After 1.660.30 1.570.30 2.050.25 2.060.29 2.010.37 1.950.33 1.820.31 1.710.33
Follow-up 1.690.38 1.200.37 2.040.32 1.260.41 1.960.42 1.730.43 1.850.35 1.690.41
RR, % 0 35                  
LL, mm 0.040.29 0.370.37 0.010.25 0.800.43 0.040.34 0.200.46 0.050.29 0.030.45
II
RD, mm
Before 2.580.14 2.600.14                  
After 2.600.27 2.710.34 2.740.21 2.810.25            
Follow-up 2.770.47 2.620.31 2.840.42 2.580.24            
MLD, mm
Before 0.970.26 0.940.21 0.970.26 0.940.21 2.290.44 2.190.50 2.000.38 2.080.40
After 1.990.26 2.060.32 2.450.27 2.410.25 2.450.31 2.480.33 2.090.31 2.220.36
Follow-up 2.060.43 1.580.50 2.440.39 1.590.53 2.380.47 2.130.45 2.230.45 2.130.32
RR, % 0 26                  
LL, mm 0.070.35 0.560.51 0.010.38 0.880.57 0.080.42 0.400.39 0.140.31 0.140.41
III
RD, mm
Before 3.250.38 3.220.30                  
After 2.990.43 3.010.33 3.180.34 3.190.29            
Follow-up 3.090.45 2.910.50 3.290.32 2.970.49            
MLD, mm
Before 1.040.41 1.130.47 1.040.41 1.130.47 2.750.59 2.750.59 2.470.46 2.550.50
After 2.310.36 2.350.27 2.810.28 2.730.31 2.980.38 2.890.45 2.510.50 2.650.32
Follow 2.350.33 1.890.46 2.860.37 2.010.56 2.960.32 2.640.62 2.600.45 2.470.43
RR, % 0 20                  
LL, mm 0.060.25 0.470.50 0.060.35 0.740.57 0.030.43 0.270.56 0.090.31 0.180.43
RR values are given as percentages; all other values are meanSD in millimeters.
RR indicates restenosis rate; and LL, late lumen loss.
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proliferative response that manifests as significantly greater
late loss at the treatment site and a resultant 2-fold increase in
in-stent restenosis in small vessels (44% versus 23%,
P0.002) as compared with nondiabetic patients with
similar-sized vessels.19 In our study, diabetes mellitus did not
attenuate the effectiveness of the sirolimus-eluting stent.
These findings contrast markedly with what was seen in the
bare stent group. Restenosis rates almost doubled from the
tertile with the largest diameter vessels to the one with the
smallest vessels (20% to 35%), whereas late loss increased
only modestly (0.74 mm to 0.80 mm). This dramatic increase
in restenosis rate is explicable on the basis of hydraulics. A
late loss of 0.80 mm in a 3.0-mm diameter vessel versus a
2.0-mm diameter vessel results in a 46% versus a 64%
obstruction. Late loss is the most sensitive and operator-
independent assessment of the effect of drug-eluting stents
and can be used to predict what the restenosis rate will be in
vessels of different diameters. Simply reporting angiographic
restenosis rates, which can be influenced by case selection
and operator techniques, is no longer sufficient in the era of
drug-eluting stents.
Conclusion
Sirolimus-eluting stents prevent neointimal proliferation and
late lumen loss irrespective of the vessel size. The classic
inverse relationship between vessel diameter and restenosis
rate was seen in the bare stent group but not in the sirolimus-
TABLE 3. Univariate Predictors of Late Loss for All Patients Treated
Univariate Predictor of Late Loss Parameter Standard Error R2 P
Treatment 0.814371 0.059535 0.4653 0.001*
MLD after procedure, mm 0.223776 0.100029 0.0227 0.026*
Age, y 0.00724 0.003924 0.0156 0.066
Total length of stents, mm 0.021843 0.012981 0.0130 0.094
Eccentric IB lesion before procedure 0.13079 0.087642 0.0106 0.137
Smoking, previous or current 0.12488 0.088079 0.0093 0.158
Diabetes mellitus 0.144408 0.103526 0.0090 0.165
Number of stents 0.222425 0.168080 0.0081 0.187
Thrombus lesion before procedure 0.28244 0.230559 0.0072 0.222
MLD before procedure, mm 0.148352 0.121476 0.0069 0.223
Diameter stenosis after procedure, % 0.03379 0.003864 0.0045 0.328
Lesion type B2 0.075694 0.082215 0.0039 0.358
Diameter stenosis after procedure, % 0.00591 0.006459 0.0039 0.361
QCA lesion length before procedure, mm 0.011469 0.012559 0.0040 0.362
Unstable angina at screening 0.072019 0.082139 0.0036 0.382
Male sex 0.080158 0.096519 0.0032 0.407
Hypertension 0.064092 0.081323 0.0029 0.432
Eccentric 1A lesion before procedure 0.064127 0.084667 0.0028 0.450
Eccentric IIa lesion before procedure 0.102716 0.138269 0.0026 0.458
Previous PTCA 0.07700 0.108119 0.0024 0.477
Previous CABG 0.20522 0.348366 0.0016 0.556
Hypercholesterolemia 0.04599 0.081463 0.0015 0.573
Eccentric IIB lesion before procedure 0.090999 0.186324 0.0011 0.626
LAD treated 0.03735 0.081421 0.0010 0.647
Readily accessible lesion before procedure 0.052347 0.132952 0.0007 0.694
Previous myocardial infarction 0.020693 0.084594 0.0003 0.807
Calcification (moderate/heavy) before
procedure
0.01526 0.096575 0.0001 0.875
Reference diameter before procedure, mm 0.003010 0.076780 0.0000 0.969
Predictors were chosen by stepwise linear regression using an entry criterion of 0.20 and a stay
criterion of 0.05.
QCA indicates quantitative coronary angiography; PTCA, percutaneous transluminal coronary
angioplasty; CABG, coronary artery bypass grafting; and LAD, left anterior descending artery.
*Significant.
TABLE 4. Multivariate Predictors of Late Loss
Multivariate Predictor of
Late Loss Parameter Standard Error R2 P
Treatment 0.810123 0.058706 0.4653 0.0001*
MLD after procedure, mm 0.196763 0.072959 0.4829 0.0076*
Predictors were chosen by stepwise linear regression using an entry
criterion of 0.20 and a stay criterion of 0.05.
*Significant P value.
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eluting stent group. This finding with the sirolimus-eluting
stent has the potential to considerably expand the use of these
stents in smaller vessels and to eliminate the present differ-
ence in reintervention rates between patients treated with
coronary artery bypass surgery and stenting.20
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